Cargando…

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies

PURPOSE: To assess the pharmacokinetics and safety of hydrochloride ophthalmic solution 0.77% olopatadine from 2 independent (Phase I and Phase III, respectively) clinical studies in healthy subjects. MATERIALS AND METHODS: The Phase I, multicenter, randomized (2:1), vehicle-controlled study was con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meier, Edward, Narvekar, Abhijit, Iyer, Ganesh R, DuBiner, Harvey B, Vutikullird, Apinya, Wirta, David, Sall, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391828/ https://www.ncbi.nlm.nih.gov/pubmed/28435218 http://dx.doi.org/10.2147/OPTH.S126690

Ejemplares similares

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Intestinal Anisakiasis Treated Successfully with Prednisolone and Olopatadine Hydrochloride
por: Toyoda, Hideki, et al.
Publicado: (2016)

Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis
por: Patel, Dharmistha, et al.
Publicado: (2018)

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis
por: Marini, María Cecilia, et al.
Publicado: (2023)

Comparison of pharmacokinetics and safety characteristics between two olopatadine hydrochloride 5 mg tablet formulations in healthy Korean subjects
por: Kim, Jae Hoon, et al.
Publicado: (2021)

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
por: Myers, Jonathan S., et al.
Publicado: (2016)

Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria
por: Makino, Teruhiko, et al.
Publicado: (2012)

The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review
por: Zi, Yingxin, et al.
Publicado: (2020)

Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety
por: Maiti, Rituparna, et al.
Publicado: (2011)

Therapeutic effects of Houttuynia eye drops combined with olopatadine hydrochloride eye drops on vernal keratoconjunctivitis
por: Xu, Xuegu, et al.
Publicado: (2019)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014)

Effects of Olopatadine Hydrochloride, a Histamine H(1) Receptor Antagonist, on Histamine-Induced Skin Responses
por: Hashimoto, Takashi, et al.
Publicado: (2010)

OLOPATADINE IN CHRONIC IDIOPATHIC URTICARIA
por: Godse, Kiran V
Publicado: (2009)

364 Zero Itch in Eyes Treated With Olopatadine Hydrochloride Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen Challenge Studies
por: Blaiss, Michael S., et al.
Publicado: (2012)

UV spectrophotometric methods for simultaneous determination of ketorolac tromethamine and olopatadine hydrochloride: Application of multiple standard addition for assay of ophthalmic solution
por: Hammad, Sherin F., et al.
Publicado: (2023)

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females
por: Xu, Yang, et al.
Publicado: (2019)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study
por: Fifer, Simon, et al.
Publicado: (2023)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies
por: Realini, T, et al.
Publicado: (2013)

Pharmacokinetics of transdermal buprenorphine patch in the elderly
por: Al-Tawil, Nabil, et al.
Publicado: (2012)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study
por: Li, Shiyu, et al.
Publicado: (2023)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

MASS DEFLECTOR APPLICATION FOR CERN’s ON-LINE ISOTOPE SEPARATOR FACILITY 077
por: Sánchez-Conejo, J
Publicado: (2004)

Bioequivalence Study of Amitriptyline Hydrochloride Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions
por: Zhai, You, et al.
Publicado: (2020)

2043: Pharmacokinetic prediction of paclitaxel-induced peripheral neuropathy
por: Hertz, Daniel L., et al.
Publicado: (2018)

A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare(®) System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease
por: Karpecki, Paul, et al.
Publicado: (2020)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors
por: Savelieva, Marina, et al.
Publicado: (2015)

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

AB077. Relationship of TPO-Ab and TSH with in vitro fertilization and embryo transfer
por: Wang, Liyun
Publicado: (2015)

MON-077 A Case of Growth Hormone Deficiency in Sturge-Weber Syndrome
por: Hwang, Jeongju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3k6civljelak2c0bakg92qlhfg